Biolargo, INC Form 4 insider transactions

BioLargo Director Dennis E. Marshall received new stock options totaling 242,645 shares at an exercise price of $0.17, compensating for services and replacing expired options.

BioLargo, Inc.'s President and Director, Dennis P. Calvert, acquired 169,498 shares of common stock at $0.2 per share by converting outstanding salary and expense debt, with the shares subject to a lock-up until specific revenue or market capitalization targets are met.

BioLargo, Inc.'s Chief Science Officer, Kenneth Reay Code, acquired 181,253 shares of common stock by converting outstanding salary and expense obligations into equity at $0.2 per share, increasing his total beneficial ownership to over 25 million shares.

BioLargo, Inc. Director Linda Park was granted options to purchase 93,750 shares of common stock at an exercise price of $0.20 per share as compensation for board services.

BioLargo, Inc. Director Jack B. Strommen received 75,000 options to purchase common stock at an exercise price of $0.20 as compensation for board services.

BioLargo, Inc. Director Christina Bray was granted 93,750 options to purchase common stock at an exercise price of $0.20 as compensation for her board services.

BioLargo, Inc. Director Dennis E. Marshall was granted 225,251 stock options at an exercise price of $0.20, including options to replace previously expired grants and for board service fees.

BioLargo's Chief Science Officer, Kenneth Reay, acquired 57,666 shares of common stock in a debt-for-equity swap, reducing the company's liabilities.

BioLargo director Jack B. Strommen received options to purchase 78,947 shares of common stock as compensation for his board service.

Director Dennis E. Marshall receives options for BioLargo shares as compensation for board service fees.

Christina Bray, a director at BioLargo, Inc., received stock options as compensation for her board service during the most recent quarterly period.

BioLargo director Linda Park acquired 98,684 shares through an option grant as compensation for board service.

BioLargo director Dennis E. Marshall received a new option grant to purchase 118,422 shares, replacing a previously expired option.

Director Jack B. Strommen receives options to purchase 65,217 shares of BioLargo stock as compensation for board service.

Director Linda Park receives options to purchase 81,522 shares of BioLargo, Inc. stock as compensation for board service.

Christina Elaine Bray, a director at BioLargo, Inc., received stock options as compensation for her board service during the most recent quarterly period.

Director Dennis E. Marshall receives option grants to purchase common stock as compensation for services and replacement of expired options.

Charles K. Dargan, CFO of BioLargo, Inc., reports the acquisition of 300,000 shares through an option grant, vesting monthly, as part of his compensation.

Director Jack B. Strommen receives options to purchase common stock in BioLargo, Inc. as compensation for board service.

Christina Elaine Bray, a director of BioLargo, Inc., acquired options to purchase 73,529 shares of common stock as compensation for board service.

Director Linda Park received an option to purchase 73,529 shares of BioLargo stock as compensation for board service.

Director Dennis E. Marshall receives stock options from BioLargo as compensation for services and board fees.

BioLargo's CFO, Charles K. Dargan, was granted an option to purchase 700,000 shares of common stock to replace a previously expired option.

Director Jack B. Strommen acquired options to purchase 42,857 shares of BioLargo, Inc. (BLGO) common stock in lieu of $15,000 in director fees.

Linda Park, a director at BioLargo, Inc. (BLGO), acquired options to purchase 53,571 shares of common stock as compensation for board service fees.

Christina Elaine Bray, a director at BioLargo, Inc. (BLGO), received options to purchase 53,571 shares of common stock as compensation for board service.

Director Dennis E. Marshall acquired options to purchase common stock in BioLargo, Inc. as compensation for services and to replace previously expired options.